| Estradiol | IC50 | 3.2 [1] |
| Estradiol | Ki | 0.21 [1] |
| Raloxifene | IC50 | 1.8 [1] |
| Tamoxifen | IC50 | 622.0 [1] |
| Tamoxifen | Ki | 31.19 [1] |
| Genistein | IC50 | 9.7 [1], 395.0 [2], 1300.0 [3] |
| Genistein | Ki | 39.0 [1], 370.0 [2] |
| Fulvestrant | IC50 | 0.06 [1], 3.4 [2] |
| Fulvestrant | Ki | 1.04 [1] |
| (Z)-4-(1-(4-(2-(Dimethylamino)ethoxy)-phenyl)-2-phenylbut-1-en-1-yl)phenol | IC50 | 5.6 [1] |
| (Z)-4-(1-(4-(2-(Dimethylamino)ethoxy)-phenyl)-2-phenylbut-1-en-1-yl)phenol | Ki | 0.04 [1], 0.39 [2], 2.51 [3], 5.7 [4] |
| (2S,3R)-3-(4-Hydroxyphenyl)-2-[4-(2-piperidin-1-ylethoxy)phenyl]-2,3-dihydro-1,4-benzoxathiin-6-ol | IC50 | 0.8 [1] |
| (2E)-3-{4-[(1E)-1,2-Diphenylbut-1-enyl]phenyl}acrylic acid | IC50 | 4000.0 [1], 12825.0 [2] |
| (E)-3-[4-[(E)-1-(4-Hydroxyphenyl)-2-phenylbut-1-enyl]phenyl]prop-2-enoic acid | IC50 | 12.0 [1], 242.0 [2] |
| (E)-3-[4-[(E)-1-(4-Hydroxyphenyl)-2-phenylbut-1-enyl]phenyl]prop-2-enoic acid | Ki | 2.51 [1] |
| Diethylstilbestrol | IC50 | 0.33 [1], 0.77 [2], 3.0 [3], 770.0 [4] |
| Diethylstilbestrol | Ki | 0.26 [1], 0.49 [2] |
| Mifepristone | IC50 | 1000.0 [1], 5000.0 [2] |
| Mifepristone | Ki | 200.0 [1], 6754.0 [2], 10000.0 [3] |
| Daidzein | IC50 | 450.0 [1], 2160.0 [2], 6300.0 [3], 17000.0 [4], 1000000.0 [5] |
| Daidzein | Ki | 1800.0 [1] |
| 4'-Hydroxytamoxifen | IC50 | 10.0 [1] |
| 4,4-Bis(3-methyl-4-hydroxyphenyl)heptane | IC50 | 4.9 [1], 4.92 [2] |
| 2-Phenyl-1-{4-[2-(piperidin-1-yl)ethoxy]phenyl}-1,2,3,4-tetrahydroisoquinolin-6-ol | IC50 | 16.5 [1] |
| Bazedoxifene | IC50 | 0.6 [1], 3.7 [2], 23.0 [3], 50.0 [4], 31710.0 [5] |
| Brilanestrant | IC50 | 0.5 [1], 6.1 [2], 11.1 [3], 24.0 [4] |
| Brilanestrant | Ki | 0.37 [1] |
| 2-(4-Fluorophenyl)-1-methyl-1-[4-(2-piperidin-1-ylethoxy)phenyl]-3,4-dihydroisoquinolin-6-ol | IC50 | 1.9 [1], 3.0 [2], 38.0 [3], 38.02 [4] |
| 2-Phenyl-1-{4-[2-(pyrrolidin-1-yl)ethoxy]phenyl}-1,2,3,4-tetrahydroisoquinolin-6-ol | IC50 | 10.69 [1], 10.7 [2], 11.5 [3], 20.99 [4], 21.0 [5] |
| (E)-3-[4-[2-Adamantylidene-(4-hydroxyphenyl)methyl]phenyl]prop-2-enoic acid | IC50 | 17.0 [1], 500.0 [2] |
| (E)-3-[4-[2-Adamantylidene-(4-hydroxyphenyl)methyl]phenyl]prop-2-enoic acid | Ki | 0.4 [1] |
| (E)-3-[4-[2-Adamantylidene-(4-hydroxyphenyl)methyl]phenyl]-N-(3-hydroxypropyl)prop-2-enamide | IC50 | 0.53 [1], 50.0 [2] |
| (E)-3-[4-[2-Adamantylidene-(4-hydroxyphenyl)methyl]phenyl]-N-(3-hydroxypropyl)prop-2-enamide | Ki | 0.43 [1] |
| Prednisolone | IC50 | 10000.0 [1], 100000.0 [2] |
| Prednisolone | Ki | 5000.0 [1] |
| Estrone | IC50 | 29.0 [1], 96.0 [2], 210.0 [3] |
| Estrone | Ki | 2.19 [1] |
| Raloxifene hydrochloride | IC50 | 0.72 [1], 2.0 [2], 2.4 [3], 22.0 [4] |
| Afimoxifene | IC50 | 10.3 [1], 17.0 [2] |
| Afimoxifene | Ki | 0.25 [1], 0.5 [2] |
| Lasofoxifene | IC50 | 1.3 [1], 1.4 [2], 3.1 [3], 4.0 [4] |
| Erteberel | Ki | 2.29 [1], 2.68 [2], 2.7 [3] |
| 2,4-Diisobutylamino-6-isopentylpyrimidine | IC50 | 3100.0 [1] |
| 2,4-Diisobutylamino-6-isopentylpyrimidine | Ki | 2800.0 [1], 29000.0 [2], 30000.0 [3] |
| 2-(4-Fluorophenyl)-1-methyl-1-[4-(2-pyrrolidin-1-ylethoxy)phenyl]-3,4-dihydroisoquinolin-6-ol | IC50 | 1.6 [1], 30.97 [2], 31.0 [3] |
| 1-Methyl-1-[4-(2-piperidin-1-ylethoxy)phenyl]-2-(3-propan-2-ylphenyl)-3,4-dihydroisoquinolin-6-ol | IC50 | 16.1 [1], 16.11 [2], 46.0 [3], 46.03 [4] |
| 1-Methyl-2-(4-methylphenyl)-1-[4-(2-piperidin-1-ylethoxy)phenyl]-3,4-dihydroisoquinolin-6-ol | IC50 | 2.9 [1], 27.99 [2], 28.0 [3] |
| 2-(4-Chlorophenyl)-1-methyl-1-[4-(2-piperidin-1-ylethoxy)phenyl]-3,4-dihydroisoquinolin-6-ol | IC50 | 3.1 [1], 34.99 [2], 35.0 [3] |
| 2-(3-Hydroxyphenyl)-1-methyl-1-[4-(2-piperidin-1-ylethoxy)phenyl]-3,4-dihydroisoquinolin-6-ol | IC50 | 0.7 [1], 33.96 [2], 34.0 [3] |
| 2-(3-Chlorophenyl)-1-methyl-1-[4-(2-pyrrolidin-1-ylethoxy)phenyl]-3,4-dihydroisoquinolin-6-ol | IC50 | 2.9 [1], 66.0 [2], 66.07 [3] |
| 2-(3-Chlorophenyl)-1-methyl-1-[4-(2-piperidin-1-ylethoxy)phenyl]-3,4-dihydroisoquinolin-6-ol | IC50 | 4.5 [1], 48.98 [2], 49.0 [3] |
| 1-Methyl-2-phenyl-1-{4-[2-(piperidin-1-yl)ethoxy]phenyl}-1,2,3,4-tetrahydroisoquinolin-6-ol | IC50 | 2.6 [1], 28.97 [2], 29.0 [3] |
| 2-(3-Fluorophenyl)-1-methyl-1-[4-(2-pyrrolidin-1-ylethoxy)phenyl]-3,4-dihydroisoquinolin-6-ol | IC50 | 3.0 [1], 38.99 [2], 39.0 [3] |
| 2-(3-Hydroxyphenyl)-1-methyl-1-[4-(2-pyrrolidin-1-ylethoxy)phenyl]-3,4-dihydroisoquinolin-6-ol | IC50 | 0.6 [1], 30.97 [2], 31.0 [3] |
| 1-Methyl-2-(4-methylphenyl)-1-[4-(2-pyrrolidin-1-ylethoxy)phenyl]-3,4-dihydroisoquinolin-6-ol | IC50 | 3.5 [1], 30.97 [2], 31.0 [3] |
| 2-(4-Chlorophenyl)-1-methyl-1-[4-(2-pyrrolidin-1-ylethoxy)phenyl]-3,4-dihydroisoquinolin-6-ol | IC50 | 3.3 [1], 26.98 [2], 27.0 [3] |
| 1-{4-[2-(Azepan-1-yl)ethoxy]phenyl}-1-methyl-2-phenyl-1,2,3,4-tetrahydroisoquinolin-6-ol | IC50 | 1.5 [1], 55.98 [2], 56.0 [3] |
| 1-Methyl-2-(4-propan-2-ylphenyl)-1-[4-(2-pyrrolidin-1-ylethoxy)phenyl]-3,4-dihydroisoquinolin-6-ol | IC50 | 2.6 [1], 43.95 [2], 44.0 [3] |
| 1-Methyl-1-[4-(2-piperidin-1-ylethoxy)phenyl]-2-(4-propan-2-ylphenyl)-3,4-dihydroisoquinolin-6-ol | IC50 | 5.2 [1], 70.96 [2], 71.0 [3] |
| 1-Methyl-2-phenyl-1-{4-[2-(pyrrolidin-1-yl)ethoxy]phenyl}-1,2,3,4-tetrahydroisoquinolin-6-ol | IC50 | 1.8 [1], 38.0 [2], 39.81 [3] |
| 2-[3-(Dimethylamino)phenyl]-1-methyl-1-[4-(2-pyrrolidin-1-ylethoxy)phenyl]-3,4-dihydroisoquinolin-6-ol | IC50 | 19.0 [1], 19.01 [2], 93.97 [3], 94.0 [4] |
| (E)-3-[4-[(7-Hydroxy-2-oxo-3-phenylchromen-4-yl)methyl]phenyl]prop-2-enoic acid | IC50 | 8.1 [1], 1180.0 [2], 1500.0 [3], 100000.0 [4] |
| (2R,3S)-3-(4-Hydroxyphenyl)-2-[4-(2-piperidin-1-ylethoxy)phenyl]-2,3-dihydro-1,4-benzoxathiin-6-ol | IC50 | 9.6 [1], 23.0 [2], 353.0 [3] |
| (E)-3-[4-[6-Hydroxy-1-methyl-2-(4-propan-2-ylphenyl)-3,4-dihydroisoquinolin-1-yl]phenyl]prop-2-enoic acid | IC50 | 0.9 [1], 1.8 [2], 2.1 [3], 30.0 [4] |
| (E)-3-[4-[3-(4-Fluoro-2-methylphenyl)-7-hydroxy-2-oxochromen-4-yl]oxyphenyl]prop-2-enoic acid | IC50 | 0.4 [1], 21.0 [2], 27.0 [3] |
| (E)-3-[4-[7-Hydroxy-3-[2-methyl-4-(trifluoromethoxy)phenyl]-2-oxochromen-4-yl]oxyphenyl]prop-2-enoic acid | IC50 | 0.5 [1], 2.7 [2], 3.9 [3] |
| (E)-3-[4-[3-(4-Fluoro-2-methylphenyl)-2-oxochromen-4-yl]oxyphenyl]prop-2-enoic acid | IC50 | 72.0 [1], 248.0 [2], 330.0 [3], 3100.0 [4] |
| (E)-3-[4-[3-[2-Methyl-4-(trifluoromethoxy)phenyl]-2-oxochromen-4-yl]oxyphenyl]prop-2-enoic acid | IC50 | 15.0 [1], 100.0 [2], 180.0 [3], 3100.0 [4] |
| 5-[4-[(3S)-1-(3-Fluoropropyl)pyrrolidin-3-yl]oxyphenyl]-6-(4-methoxy-2-methylphenyl)-8,9-dihydro-7H-benzo[7]annulen-2-ol | IC50 | 0.2 [1], 1.0 [2], 12.0 [3], 16.0 [4] |
| 6-(3-Fluoro-4-methoxyphenyl)-5-[4-[(3S)-1-(3-fluoropropyl)pyrrolidin-3-yl]oxyphenyl]-8,9-dihydro-7H-benzo[7]annulen-2-ol | IC50 | 0.3 [1], 4.0 [2], 67.0 [3], 120.0 [4] |
| 6-[4-(Difluoromethoxy)-2-fluorophenyl]-1-fluoro-5-[4-[(3S)-1-(3-fluoropropyl)pyrrolidin-3-yl]oxyphenyl]-8,9-dihydro-7H-benzo[7]annulen-2-ol | IC50 | 0.2 [1], 2.0 [2], 27.0 [3], 47.0 [4] |
| CID 130232950 | IC50 | 0.2 [1], 2.0 [2], 29.0 [3], 50.0 [4] |
| 5-[4-[(3S)-1-(3-Fluoropropyl)pyrrolidin-3-yl]oxyphenyl]-6-(1-methyl-3,6-dihydro-2H-pyridin-4-yl)-8,9-dihydro-7H-benzo[7]annulen-2-ol | IC50 | 38.0 [1], 284.0 [2], 728.0 [3], 937.0 [4] |
| 5-[4-[(3S)-1-(3-Fluoropropyl)pyrrolidin-3-yl]oxyphenyl]-6-(3-hydroxyphenyl)-8,9-dihydro-7H-benzo[7]annulen-2-ol | IC50 | 0.7 [1], 2.0 [2], 3.0 [3], 4.0 [4] |
| 5-[4-[(3S)-1-(3-Fluoropropyl)pyrrolidin-3-yl]oxyphenyl]-6-(2-methyl-1,3-benzoxazol-6-yl)-8,9-dihydro-7H-benzo[7]annulen-2-ol | IC50 | 0.3 [1], 1.0 [2], 11.0 [3], 18.0 [4] |
| [(5Z)-Cyclodec-5-en-3,7-diyn-1-yl]methyl 3-[(8R,9S,13S,14S,17S)-3,17-dihydroxy-13-methyl-7,8,9,11,12,14,15,16-octahydro-6H-cyclopenta[a]phenanthren-17-yl]prop-2-ynoate | IC50 | 10000.0 [1], 31000.0 [2], 33000.0 [3], 48000.0 [4] |
| Ethinyl estradiol | IC50 | 2.0 [1], 8.04 [2] |
| Ethinyl estradiol | Ki | 0.13 [1] |
| Spironolactone | IC50 | 5702.0 [1], 20000.0 [2] |
| Spironolactone | Ki | 1100.0 [1] |
| Coumestrol | IC50 | 11.0 [1], 75.7 [2] |
| Pipendoxifene | IC50 | 1.5 [1], 14.0 [2], 60.0 [3] |
| (E)-3-[3,5-Difluoro-4-[(1R,3R)-2-(2-fluoro-2-methylpropyl)-3-methyl-1,3,4,9-tetrahydropyrido[3,4-b]indol-1-yl]phenyl]prop-2-enoic acid | IC50 | 0.14 [1], 0.21 [2], 0.68 [3] |
| (2S,3R)-3-(4-Hydroxyphenyl)-2-[4-[2-[(3R)-3-methylpyrrolidin-1-yl]ethoxy]phenyl]-2,3-dihydro-1,4-benzoxathiin-6-ol | IC50 | 3.0 [1] |
| (2S,3R)-3-(4-Hydroxyphenyl)-2-[4-(2-pyrrolidin-1-ylethoxy)phenyl]-2,3-dihydro-1,4-benzoxathiin-6-ol | IC50 | 2.6 [1] |
| (2S,3R)-3-(3-Hydroxyphenyl)-2-[4-(2-pyrrolidin-1-ylethoxy)phenyl]-2,3-dihydro-1,4-benzoxathiin-6-ol | IC50 | 0.9 [1], 1.0 [2], 1.7 [3] |
| (3Ar,4S,9bS)-4-(4-hydroxyphenyl)-1,2,3,3a,4,9b-hexahydrocyclopenta[c]chromen-8-ol | Ki | 4.34 [1], 14.5 [2] |
| (2S,3R)-3-(3-Hydroxyphenyl)-2-[4-(2-piperidin-1-ylethoxy)phenyl]-2,3-dihydro-1,4-benzoxathiin-6-ol | IC50 | 4.0 [1], 4.1 [2], 5.4 [3] |
| 6-Butyl-2,4-dipropylaminopyrimidine | IC50 | 13000.0 [1] |
| 6-Butyl-2,4-dipropylaminopyrimidine | Ki | 16000.0 [1], 32000.0 [2] |
| (2R,3S)-3-(4-Hydroxyphenyl)-2-[4-(2-piperidin-1-ylethoxy)phenyl]-2,3-dihydro-1,4-benzoxathiin-7-ol | IC50 | 1.6 [1], 1.8 [2], 5.0 [3] |
| 2-N,4-N-Dibenzyl-6-(2-phenylethyl)pyrimidine-2,4-diamine | IC50 | 1000000.0 [1] |
| 2-N,4-N-Dibenzyl-6-(2-phenylethyl)pyrimidine-2,4-diamine | Ki | 49000.0 [1], 1000000.0 [2] |
| 1-[2-[4-[(19R)-5,15-Dimethoxy-8,18-dioxatetracyclo[9.8.0.02,7.012,17]nonadeca-1(11),2(7),3,5,12(17),13,15-heptaen-19-yl]phenoxy]ethyl]piperidine | IC50 | 64.0 [1], 1736.0 [2], 10000.0 [3] |
| Chembl4171598 | IC50 | 0.9 [1], 53.0 [2] |
| Chembl4171598 | Ki | 0.5 [1] |
| (19R)-15-Methoxy-19-[4-(2-piperidin-1-ylethoxy)phenyl]-8,18-dioxatetracyclo[9.8.0.02,7.012,17]nonadeca-1(11),2(7),3,5,12(17),13,15-heptaen-5-ol | IC50 | 9.0 [1], 10.0 [2], 259.0 [3] |
| (E)-3-[4-[[2-[2-(1,1-Difluoroethyl)-4-fluorophenyl]-6-hydroxy-1-benzothiophen-3-yl]oxy]phenyl]prop-2-enoic acid | IC50 | 0.2 [1], 6.0 [2], 8.9 [3] |
| 9a-Benzyl-7-hydroxy-4-methyl-1,2,9,9a-tetrahydro-3H-fluoren-3-one | IC50 | 14.0 [1], 1500.0 [2], 2300.0 [3] |